RE:CAR-T is getting Competitive between big Pharmas tooI have posted in the past about the advantages of pelareorep + ICI to "enable" CAR-T and bispecific therapies in the treatment of soldi tumors, particularly as ONCY's pelareorep 'pre-conditions' the tumor microenvironmet (TME) for both adoptive T-cell therapies.
For example refer to:
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy - Christianne Groeneveldt et al. - Dec 2020
Results of this study demonstrated that replication-competent reovirus induced an early interferon signature, followed by a strong influx of natural killer cells and CD8+T cells, at the cost of FoxP3+ Tregs, and that the tumor-infiltrating T cells produced by reovirus served as nonexhausted effector cells for the subsequently systemically administered CD3-bsAbs.
The ability of reovirus to generate tumor-infilitrating T-cells as non-exhausted effector cells, as well as overcoming an immunosuppressive TME, thus sets up the right conditions for immune checkpoint inhibitor additions.
Then in June 2021 the following review appeared which concluded what follows:
"Key Developments in Cancer Immunotherapy Over the Last Decade" - Dr Georgia McDonald
Sub-title: Checkpoint inhibitors - Adoptive Cell Therapy (CAR-T therapy) - Cancer Vaccines - Oncolytic virus
"Oncolytic virus therapy represents a particularly promising role in combination with other immunotherapies that rely on the presence of robust anti-cancer lymphocytic populations, such as checkpoint inhibitors and cellular therapy. In fact, more than a third of the current ongoing oncolytic viral therapy trials involve their combination with immune checkpoint inhibitor drugs."
Now the Mayo Clinic's Dr. Richard Vile and his team have demonstrated that ONCY's pelareorep "primes" the adaptive immune system for effective CAR-T therapy and a 'curative' effect in solid tumors, was seen when a second dose of pelareorep was administered as a "boost" which had the effect of re-activating senescent CAR-T cells that were present from the original CAR-T infusion, further stimulating the immuno system and elimination of remaining tumor cells - resulting in a 'curative' effect of this IO combination treatment.
This is all good for ONCY.